Parabilis Medicines, Inc. announced that its Chief Medical Officer, Fawzi Benzaghou, M.D., mutually agreed to transition from the company effective September 30, 2026. Dr. Benzaghou will receive severance benefits in accordance with his employment agreement. Parabilis Medicines operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.
